GlassScriptPhysician profile
Jiun Yoon
NPI 1548258783
$7,136.24
in general payments reported to CMS, 2019-2025
21 companies · $1,562 in 2025
The $1,562 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $969 · 2020: $837 · 2021: $765 · 2022: $764 · 2023: $1,026 · 2024: $1,214 · 2025: $1,562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,517 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,516.72 |
| Education | $284.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,454.60 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,401.81 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $800.25 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $730.79 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $717.63 | 2019-2025 | |
| Kaleo, INC. | $333.21 | 2019-2024 | Auvi-Q |
| Abbvie INC. | $255.59 | 2022-2024 | Rinvoq |
| Optinose US, INC. | $242.30 | 2019-2023 | |
| Incyte Corporation | $187.07 | 2021-2023 | Opzelura |
| Genentech USA, INC. | $157.20 | 2021-2025 | Xolair |
| Sanofi-Aventis U.S. LLC | $135.99 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $135.64 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $124.29 | 2023 | Orladeyo |
| Novartis Pharmaceuticals Corporation | $99.04 | 2025 | |
| Blueprint Medicines Corporation | $90.13 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $88.12 | 2022-2023 | Tezspire |
| Lilly USA, LLC | $85.30 | 2024-2025 | Ebglyss |
| Jubilant Hollisterstier LLC | $31.33 | 2024 | |
| Alexion Pharmaceuticals, INC. | $29.11 | 2024 | Strensiq |
| Alk-Abello, INC | $20.43 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jiun Yoon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.